Charles Augenbraun, MD
Cardiovascular Disease · Norwalk, CTNPI 1205930997
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 74 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $930 and has fallen 84.3% since, to $146 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in CT, where the typical reported total is $1,107.
Across 74 payments — averaging $20.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$337
- Novartis$327
- Johnson & Johnson$190
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$163
- Boehringer Ingelheim$100
- Sanofi-aventis U.S. LLC$97
- plus $278 from 7 others
Across 22 payments — averaging $18,281 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$280K
- Amgen$91K
- Merck$16K
- Boehringer Ingelheim$10K
- AstraZeneca$5K
What the payments were for
- Food & beverage$1,47399%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 12 | $337 |
| Novartis | 16 | $327 |
| Johnson & Johnson | 14 | $190 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $163 |
| Boehringer Ingelheim | 6 | $100 |
| Sanofi-aventis U.S. LLC | 5 | $97 |
| Cvrx, Inc. | 1 | $81 |
| Esperion Therapeutics, Inc. | 2 | $53 |
| E.r. Squibb & Sons, L.L.C. | 3 | $44 |
| Regeneron Healthcare Solutions, Inc. | 2 | $34 |
| Portola Pharmaceuticals, LLC | 2 | $30 |
| Amarin Pharma, Inc. | 1 | $22 |
| Pfizer | 1 | $14 |
How this compares
$1,492 in reported general payments places this provider in the 50th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 295 | $391,764 |
| Repatha SureclickEvolocumab | 176 | $206,650 |
| XareltoRivaroxaban | 65 | $83,987 |
| Praluent PenAlirocumab | 60 | $54,739 |
| EntrestoSacubitril/Valsartan | 33 | $52,478 |
| JardianceEmpagliflozin | 22 | $15,454 |
| Metoprolol Succinate | 483 | $6,799 |
| Atorvastatin Calcium | 679 | $6,743 |
| Nebivolol Hcl | 53 | $3,593 |
| Losartan Potassium | 378 | $3,408 |
| Ezetimibe | 122 | $2,920 |
| Amlodipine Besylate | 360 | $2,465 |
| Rosuvastatin Calcium | 173 | $2,124 |
| Doxazosin Mesylate | 72 | $1,749 |
| Valsartan | 52 | $1,634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $391,764295 claims |
| Johnson & JohnsonXarelto | $190 | $83,98765 claims |
| NovartisEntresto | $327 | $52,47833 claims |
| Boehringer IngelheimJardiance | $100 | $15,45422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 415 cardiovascular disease providers in Connecticut.
Other cardiovascular disease in Norwalk
- Nihar DesaiNew Haven$1.4M
- Brett NowlanBloomfield$798K
- Jeffery TestaniNew Haven$546K
- Carlos Mena-HurtadoNew Haven$460K
- Stephanie SaucierHartford$243K
- John ForrestNew Haven$164K
- Henry WardNew Haven$152K
- Ricardo CordidoHamden$135K
- Antonio FernandezHartford$113K
- Paul ThompsonHartford$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.